Psilocybin-assisted Psychotherapy for Cancer Survivors

Recruiting in Palo Alto (17 mi)

Overseen byMoran Amit, MD, PHD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This clinical research study is to learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors with depression and/or anxiety.

Research Team

Moran Amit, MD, PHD

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for adult cancer survivors who are now free of disease but suffer from depression and/or anxiety. They must not have brain involvement, be fluent in English, able to travel for sessions, and agree to avoid certain substances. Excluded are those with a high suicide risk, recent severe depression before cancer diagnosis, pregnant women or without contraception use, vulnerable populations like children or cognitively impaired individuals.

Inclusion Criteria

I will stop taking certain enzyme inhibitors before taking psilocybin.

My cancer does not affect my brain.

I am 18 years old or older.

See 10 more

Exclusion Criteria

My close family has a history of specific mental health conditions.

My current cancer treatment is aimed at easing symptoms.

Clinically significant suicidality or high risk of completed suicide

See 17 more

Treatment Details

Interventions

Psilocybin (Psychedelic Therapy)

Trial OverviewThe TRIPS study tests psilocybin-assisted psychotherapy's safety and effectiveness on cancer survivors with depression/anxiety. Participants will undergo therapy sessions where they'll receive psilocybin—a substance found in magic mushrooms—to see if it helps improve their mental health conditions.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Treatment with PsilocybinExperimental Treatment1 Intervention